Serum cartilage oligomeric matrix protein levels as a novel non-invasive biomarker for liver fibrosis in patients with chronic viral hepatitis? It is too early

Introduction. In recent years there have been major advances in the treatment and prevention of viral hepatitis, but this pathology is still a major health and socio-economic problem. The defining element for this disease is the liver fibrosis, a histological component of particular importance due to its role in the formation of liver lesions of cirrhosis. Thus, an essential step in the management of chronic viral hepatitis is the detection and measurement of liver fibrosis. Today we have invasive methods for detecting liver fibrosis, the liver puncture biopsy, and non-invasive methods, which in turn are divided into serum methods and imaging methods (2). Purpose of the Study. The aim of this study is to determine if transcutaneous elastography (FibroScan) is equally reliable in case of viral hepatitis B, as with viral hepatitis C. Material and Method: The study comprises a total of 1,127 patients with liver disease of HBV and HCV aetiology. These patients were examined using FibroScan in the period July 2009 - April 2011. Results: Of the 1,177 patients investigated using FibroScan, 40 underwent liver biopsy as well. Of these, 82% have obtained same stages of liver fibrosis in these two investigations, and 18% achieved different stages of fibrosis in these two tests. For the patients with HCV infection, we obtained a 67.81% match of the two non-invasive tests, FibroScan and FibroMax, and a 79.16% match of FibroScan compared to the Liver Biopsy. For the B virus, the compliance is even better, of 75% (FibroScan - FibroMax), and 80% for FibroScan - LB. Conclusions: FibroScan is one of the non-invasive assessment methods of liver fibrosis with diagnose accuracy similar to FibroMax and close to Liver Biopsy.

Download Full-text

Possibilities of non-invasive determination of the stage of liver fibrosis in patients with chronic viral hepatitis C and metabolic syndrome

Infekcionnye bolezni ◽

10.20953/1729-9225-2018-3-46-50 ◽

2018 ◽

Vol 16 (3) ◽

pp. 46-50

Author(s):

D.Yu. Konstantinov ◽

◽

A.F. Novikova ◽

G.V. Nedugov ◽

A.A. Suzdaltsev ◽

...

Keyword(s):

Metabolic Syndrome ◽

Hepatitis C ◽

Liver Fibrosis ◽

Viral Hepatitis ◽

Chronic Viral Hepatitis ◽

Non Invasive ◽

Viral Hepatitis C ◽

Chronic Viral Hepatitis C

Download Full-text

CHRONIC VIRAL HEPATITIS B;

The Professional Medical Journal ◽

10.29309/tpmj/2018.25.08.46 ◽

2018 ◽

Vol 25 (08) ◽

pp. 1218-1222

Author(s):

Nasreen - ◽

Aqeel Ahmed Channa ◽

Abdul Raheem Memon ◽

Syed Zulfiquar Ali Shah ◽

Muhammad Iqbal

Keyword(s):

Liver Fibrosis ◽

Hepatitis B ◽

Viral Hepatitis ◽

Chronic Viral Hepatitis ◽

University Hospital ◽

Female Population ◽

Male And Female ◽

Non Invasive ◽

Viral Hepatitis B ◽

The Mean

Objectives: To determine the frequency of liver fibrosis by non invasive markerin patients with chronic viral hepatitis B. Study Design: Cross sectional clearly investigate aboutchronic viral hepatitis population. Setting: Liaquat University Hospital Hyderabad. Period: Sixmonths, 09-Jan-2014 to 08-July-2014. Patients and Methods: All the patients of 16-50 years ofage, of either gender with chronic viral hepatitis B infection for more than 6 months duration wereadmitted and evaluated for liver fibrosis through non invasive marker (APRI). The SPSS was usedto manipulate the data. Results: During six month study period, total 140 patients with chronicviral hepatitis B infected patients were evaluated for liver fibrosis. Majority of patients were fromurban areas 112/140 (80%). The mean ±SD for age of patients with chronic viral hepatitis Binfection was 37.95±9.77. The mean age ±SD of hepatic fibrotic patients was 35.72±7.62.The mean ±SD for age of male and female population was 35.83±8.74 and 33.83 ± 6.53respectively. The mean ± SD for APRI score in hepatic fibrotic subjects was 1.31±0.31 while inrelation to liver fibrotic male and female patients it was 0.91±0.21 and 1.00±0.32 respectively.Majority of the subjects were 30-39 years of age and the male population predominant (p=0.02)whereas the liver fibrosis was identified in 89/140 (63.5) [p=<0.01] as far as gender distributionis concerned. Conclusion: APRI may be used as a simple and readily available tool for thediagnosis of significant fibrosis in patients with chronic viral hepatitis B.

Download Full-text

Non-invasive assessment of liver fibrosis using acoustic structure quantification: comparison with transient elastography in chronic viral hepatitis

Abdominal Radiology ◽

10.1007/s00261-015-0597-3 ◽

2015 ◽

Vol 41 (2) ◽

pp. 239-247 ◽

Cited By ~ 6

Author(s):

Tae-Hoon Nam ◽

Beom Jin Park ◽

Deuk Jae Sung ◽

Min Ju Kim ◽

Na Yeon Han ◽

...

Keyword(s):

Liver Fibrosis ◽

Viral Hepatitis ◽

Transient Elastography ◽

Chronic Viral Hepatitis ◽

Acoustic Structure ◽

Non Invasive ◽

Acoustic Structure Quantification

Download Full-text

Cartilage oligomeric matrix protein as a marker of progressive liver fibrosis in biliary atresia

Scientific Reports ◽

10.1038/s41598-021-95805-x ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Wanvisa Udomsinprasert ◽

Napat Angkathunyakul ◽

Jiraphun Jittikoon ◽

Usa Chaikledkaew ◽

Paisarn Vejchapipat ◽

...

Keyword(s):

Liver Fibrosis ◽

Biliary Atresia ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

Early Stage ◽

Characteristic Curve ◽

Enzyme Linked Immunosorbent Assay ◽

Healthy Controls ◽

Protein Levels ◽

Protein Expressions

AbstractThis study aimed to determine whether mRNA and protein levels of cartilage oligomeric matrix protein (COMP), a glycoprotein responsible for modulating homeostasis of extracellular matrix, in the systemic and local liver environments were associated with clinical parameters of biliary atresia (BA) patients and might serve as a biomarker for BA severity. COMP protein levels in the circulation of 96 BA patients and 56 healthy controls and its mRNA and protein expressions in the liver of 20 BA patients and 5 non-BA patients were evaluated using enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and immunohistochemistry, respectively. In the circulation of BA patients, COMP levels were significantly higher than those in healthy controls. Compared with early-stage BA patients, those with advanced-stage including jaundice, fibrosis, and hepatic dysfunction had significantly increased circulating COMP levels. Raised circulating COMP levels were found to be independently correlated with degree of liver fibrosis. Survival analysis showed that elevated circulating COMP levels were significantly associated with decreased survival of BA patients. Receiver-operating characteristic curve analysis unveiled a diagnostic value of circulating COMP as a non-invasive biomarker of BA (AUC = 0.99), with a sensitivity of 100.0% and a specificity of 98.2%. In the liver, both COMP mRNA and protein expressions of BA patients with fibrosis were significantly greater than those of BA patients without fibrosis and non-BA patients. Collectively, increased circulating COMP might reflect unfavorable outcome of BA patients and have potential as a novel biomarker for the disease severity following Kasai-operation.

Download Full-text